Updates are available Correction dated 2023-07-05
Click to view Correction: https://doi.org/10.1007/s10067-023-06692-8
-
Authors
Tesch, Falko http://orcid.org/0000-0001-8933-643X
Ehm, Franz http://orcid.org/0000-0003-3749-4000
Vivirito, Annika
Wende, Danny http://orcid.org/0000-0002-0545-0807
Batram, Manuel http://orcid.org/0000-0003-4445-965X
Loser, Friedrich
Menzer, Simone
Jacob, Josephine http://orcid.org/0000-0001-8769-9747
Roessler, Martin http://orcid.org/0000-0002-4662-4156
Seifert, Martin
Kind, Barbara
König, Christina
Schulte, Claudia
Buschmann, Tilo
Hertle, Dagmar
Ballesteros, Pedro
Baßler, Stefan
Bertele, Barbara
Bitterer, Thomas
Riederer, Cordula
Sobik, Franziska
Reitzle, Lukas http://orcid.org/0000-0001-7095-6567
Scheidt-Nave, Christa http://orcid.org/0000-0002-1902-7567
Schmitt, Jochen http://orcid.org/0000-0003-0264-0960
-
Funding
Funding for this research was provided by:
Bundesministerium für Gesundheit (ZMI1-2521NIK705)
Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden
- License Information
-
More Information
Article History
Received: 25 January 2023
Revised: 11 May 2023
Accepted: 8 June 2023
First Online: 19 June 2023
Change Date: 5 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10067-023-06692-8
Compliance with ethical standards
:
: The study was approved by the ethics committee of the TU Dresden (approval number: BO-EK (COVID)-482102021) and adheres to all relevant administrative and legal regulations. The study was registered at ExternalRef removed (NCT number: NCT05606198).
: FT, FE, AV, MS, JJ, BK, LR, CS, and JS and report institutional funding for this project from the German Federal Ministry of Health. Unrelated to this study, JS reports grants for investigator-initiated research from the German GBA, the BMG, BMBF, EU, Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer. He also participated in advisory board meetings for Sanofi, Lilly, and ALK. MB reports payment for data analysis which is presented in this paper from DAK-Gesundheit. Unrelated to this study, MB reports grants from German GBA, Pfizer, and Sanofi Pasteur and consulting fees from Janssen-Cilag. He participated in an advisory board for GSK. The other authors declare that they have no competing interest.
